AYDINOK, Y. Et Al. 2016. Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , (California, United States Of America).

AYDINOK, Y., Karakas, Z., Cassinerio, E., Siritanaratkul, N., Kattamis, A., Maggio, A., ... Hollaender, N.(2016). Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study . 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America

AYDINOK, YEŞİM Et Al. "Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study," 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 2016

AYDINOK, YEŞİM Et Al. "Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , California, United States Of America, 2016

AYDINOK, Y. Et Al. (2016) . "Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , California, United States Of America.

@conferencepaper{conferencepaper, author={YEŞİM AYDINOK Et Al. }, title={Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study}, congress name={58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)}, city={California}, country={United States Of America}, year={2016}}